BRAF and intrahepatic cholangiocarcinoma: Moreover, promising results of human epidermal growth factor receptor-2–targeted therapies for Erb-B2 receptor tyrosine kinase 2 (ERBB2) amplified BTC and a combination of BRAF plus MEK inhibitors for ICC harboring serine/threonine protein kinase B-Raf (BRAF) V600E have emerged (11, 12).